Full-Time

Senior Staff Accountant

Posted on 8/20/2024

Telix Pharmaceuticals

Telix Pharmaceuticals

501-1,000 employees

Develops targeted radiation therapies for cancer

No salary listed

Senior

Fishers, IN, USA

Candidates should expect to be in the office at minimum 3 days per week; local candidates are preferred.

Category
Cost Accounting
Financial Accounting
Financial Analysis
Management Accounting
Accounting
Required Skills
SAP Products
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Telix Pharmaceuticals referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Bachelor's degree in Finance or Accounting, MBA preferred.
  • Certified Public Accountant or equivalent certification highly preferred.
  • 5-7 years of progressive accounting experience, including a solid background in financial reporting, general ledger management, and month-end/year-end processes.
  • Experience with international accounting standards or working in a global organization.
  • Strong proficiency in SAP or other accounting software programs.
  • Excellent analytical, problem-solving, and detail-oriented skills.
  • Demonstrated involvement in mergers and acquisitions with an understanding of closing/purchase price accounting transactions.
  • Excellent communication and organizational skills.
Responsibilities
  • Ensure timely recording, analyzing and reporting of accounting transactions.
  • Ensure full and complete balancing of intercompany transactions to allow for proper elimination at group level.
  • Co-lead and participate in month-end and year-end close activities, including journal entry posting, reconciliations, accruals, and financial reporting.
  • Complete inventory confirmations, journal entries and transfer pricing transactions within the accounting system.
  • Partner with FP&A team to analyze monthly activity to explain reporting variances and enhance forecasting.
  • Collaborate with various teams and team members regarding SOX compliance activities, internal and external audits.
  • Provide back-up and support for other accountants and ensure proper cross training.
  • Assist in purchase price accounting transactions and opening balance sheet for mergers and acquisitions.
  • Understand and support revenue recognition in accordance with ASC606 and IFRS 15.
  • Understand, support and record transactions related to right our use assets, leases, ASC842.
  • Understand, support, record and reconcile transactions related to various tangible and intangible assets.
  • Develop and maintain documentation related to accounting policies and procedures, ensuring alignment with company guidelines and best practices.
  • Support the review of financial statements for a variety of legal entities, in multiple currencies, to ensure completeness and accuracy of financial data in compliance with accounting standards, GAAP & IFRS.
  • Stay abreast of changes in accounting standards and regulations, evaluating their impact on the organization, and implementing necessary adjustments.
  • Collaborate with stakeholders to provide guidance on financial principles and address any related inquiries or concerns.
  • Embody a shared services mindset to work cross functionally and with a variety of teams.
  • Participate in cross-functional initiatives and projects aimed at improving processes, systems, and controls.
  • Ensure adherence to regulatory requirements, accounting standards, and internal controls related to revenue recognition and rebate programs.
  • Assist in internal and external audits by providing documentation, explanations, and support related to revenue and revenue related processes, controls, and compliance.
  • Implement corrective actions and improvements based on audit findings and recommendations.
  • All other duties as assigned, which may change from time to time to meet business needs.
Telix Pharmaceuticals

Telix Pharmaceuticals

View

Telix Pharmaceuticals develops and sells products for diagnosing and treating cancer and rare diseases using targeted radiation. Their products aim to enhance treatment decisions and offer personalized therapies for conditions that lack effective solutions. The company focuses on areas such as prostate and kidney cancers, glioma, sarcoma, and bone marrow conditioning. Telix operates a global supply chain to manufacture and distribute its specialized products to healthcare providers and patients. Unlike many competitors, Telix emphasizes sustainability, patient care, and ethical practices in its operations. The company's goal is to improve the quality of life for patients while creating sustainable value for all stakeholders.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Melbourne, Australia

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA's priority review for TLX250-CDx highlights potential market entry for innovative imaging agents.
  • Promising IPAX-Linz study results could boost interest in Telix's neuro-oncology pipeline.
  • Collaboration with IRE ELiT S.A. expands Telix's market presence in Europe.

What critics are saying

  • Increased competition from Novartis and Bayer may impact Telix's market share.
  • Supply chain vulnerabilities in radioisotope production could affect product availability.
  • Rapid technological advancements could render Telix's current technologies obsolete.

What makes Telix Pharmaceuticals unique

  • Telix focuses on molecularly-targeted radiation therapy for prostate, renal, and glioblastoma cancers.
  • The company integrates sustainability and patient care into its biopharmaceutical operations.
  • Telix has a robust global supply chain for its diagnostic and therapeutic products.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Annual Performance Bonus

Equity-Based Incentive Program

Paid Vacation

Paid Wellness Days

Hybrid Work Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↑ 0%

2 year growth

↑ 0%
Telix Pharmaceuticals
Apr 28th, 2025
Telix's Illuccix PSMA-PET Imaging Agent Approved in France

Telix will partner with IRE ELiT S.A. (the radiopharmaceutical subsidiary of IRE Group), a leading provider of radioisotopes and radiopharmaceuticals for nuclear medicine, for the marketing and promotion of Illuccix(R) to healthcare professionals in France.

Telix Pharmaceuticals
Apr 25th, 2025
AUA25: Telix to Showcase Urologic Pipeline at AUA: ProstACT Global, Illuccix(R) and Zircaix(R)

AUA25: Telix to showcase urologic pipeline at AUA: ProstACT Global, Illuccix(R) and zircaix(r).

PR Newswire
Apr 15th, 2025
Ipax-Linz Study Reports Promising Efficacy For Tlx101 Glioma Therapy Candidate

MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan[1]) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 study[2]. IPAX-Linz is a single-arm Phase 2 investigator-initiated trial (IIT). IPAX-Linz evaluates the safety, tolerability and preliminary efficacy of TLX101 therapy, in combination with external beam radiation therapy (EBRT). The target patient population is patients at first or second recurrence with high-grade gliomas (HGG), including glioblastoma. Treatment with TLX101 was well tolerated with no serious adverse events reported. IPAX-Linz demonstrated encouraging preliminary efficacy data, indicating a median overall survival (OS) of 12.4 months from the initiation of treatment with TLX101, or 32.2 months from initial diagnosis[3]

Siam News Network
Apr 6th, 2025
Telix Appoints Paul Schaffer as Chief Technology Officer

MELBOURNE, Australia and INDIANAPOLIS, April 7, 2025 /PRNewswire/ - Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that is has appointed Dr. Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today.

Telix Pharmaceuticals
Apr 3rd, 2025
Anne Whitaker Appointed as Non-Executive Director

Telix today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 2025[1].

INACTIVE